Search
Trolamine salicylate Action Pathway
smpdb.ca/view/SMP0126096Drug actionIt targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. … The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2.
Drugs: Glutathione · Dinoprostone · Calcium · Mesoheme · Prostaglandin G2 · Arachidonic Acid +1 moreEnzymes: Prostaglandin E synthaseDexketoprofen Action Pathway
smpdb.ca/view/SMP0126113Drug actionProstaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase, or prostaglandin E2 via prostaglandin E synthase. … Because dexketoprofen decreases PGE2 in the CNS, it has an antipyretic effect. Antipyretic effects result in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.
Enzymes: Prostaglandin E synthaseSulindac Action Pathway (New)
smpdb.ca/view/SMP0126555Drug actionThis results in the inhibition of the cyclooxygenase pathway. … The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2.
Enzymes: Prostaglandin E synthaseNabumetone NSAID Action Pathway
smpdb.ca/view/SMP0124604Drug actionProstaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase or prostaglandin E2 via prostaglandin E synthase. … Cytokines are produced in the central nervous system (CNS) during an inflammatory response.
Enzymes: Prostaglandin E synthaseZolbetuximab
go.drugbank.com/drugs/DB15118ApprovedInvestigational[L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … Zolbetuximab (previously claudiximab)[A264748] is a chimeric cytolytic antibody comprising variable regions derived from mouse anti-human claudin-18 isoform 2 monoclonal antibody and constant regions derived
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalinclude lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGTislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigational[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsTenofovir disoproxil
go.drugbank.com/drugs/DB00300ApprovedInvestigationalThis drug is prescribed in combination with other drugs for the management of HIV infection as well as for Hepatitis B therapy. Tenofovir disoproxil was initially approved in 2001 [FDA label]. … Tenofovir disoproxil fumarate (a prodrug of tenofovir), marketed by Gilead Sciences under the trade name _Viread_, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase
Mixtures: TOLAK® E 300/200, TOLAK® E 300/200Categories: Antivirals used in combination for the treatment of HIV infections, P-glycoprotein inhibitorsFerrous fumarate
go.drugbank.com/drugs/DB14491ApprovedInvestigationalUsed in treatment of iron deficiency anemia.
Synonyms: Iron(2+) fumarateMixtures: Ribotin-E, Supravite Stress Avec Vit E Et FerSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: SUNITINIB EG, DOSTINIB® 25MG